샘플 요청 목록

 카트 문의
시장보고서
상품코드
1566352

세계의 프로스타글란딘 아날로그 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 투여 경로별, 약제 유형별, 용도별, 유통 채널별, 지역별 시장 예측(2024-2032년)

Prostaglandin Analogs Market Size, Share, Trends, Industry Analysis Report: By Route of Administration, By Drug Type, By Application, By Distribution Channel, and By Region - Market Forecast, 2024 - 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 세계 프로스타글란딘 아날로그 시장 규모는 2032년까지 65억 6,671만 달러에 이를 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

프로스타글란딘 아날로그 시장은 주로 녹내장 관리의 역할에 의해 견인되는 제약 산업의 중요한 부문입니다. Latanoprost, Bimatoprost, Travoprost를 포함한 이러한 의약품은 녹내장을 조절하는 데 중요한 요소인 안압(IOP)을 낮추기 위한 첫 번째 선택 약물로 널리 사용됩니다. 이러한 약물 시장 우위는 입증된 효능과 좋은 안전성 프로파일에 기인하며, 장기적인 녹내장 관리에 바람직한 선택이 되었습니다.

프로스타글란딘 아날로그 시장의 성장에는 몇 가지 중요한 요인이 기여합니다. 녹내장의 유병은 돌이킬 수 없는 실명의 주요 원인이며 효과적이고 신뢰할 수있는 치료 옵션이 필요합니다. 프로스타글란딘 아날로그는 안압을 현저히 낮추고 시력 저하를 방지함으로써 이러한 요구에 대응합니다. 또한, 제형 및 약물 전달의 지속적인 발전으로 환자의 컴플라이언스와 치료 성적이 향상되었습니다. 새로운 제형과 조합에 대한 지속적인 임상 연구는 효능과 안전성 프로파일을 개선함으로써 시장 성장을 더욱 강화하고 있습니다.

전반적으로, 프로스타글란딘 아날로그 시장은 효과적인 녹내장 치료에 대한 긴급한 필요, 지속적인 혁신, 장기 치료를 필요로 하는 환자 수 증가에 의해 견인되고 있습니다.

프로스타글란딘 아날로그 시장 보고서 하이라이트

Latanoprost는 녹내장 환자의 안압 하강에 대한 효능이 입증되었기 때문에 프로스타글란딘 아날로그 시장을 독점하고 있으며, 이 범주에서 가장 널리 처방되는 약물이 되었습니다.

국소 투여는 특히 녹내장이나 고안압증과 같은 안질환 관리에서 전신적인 부작용이 적고 치밀한 치료를 제공하기 때문에 시장을 선도하고 있습니다.

녹내장 치료는 녹내장 세계의 유병률 증가와 안압 하강에서 프로스타글란딘 유사체의 효능에 의해 가장 큰 부문이 되었습니다.

병원 약국은 가장 큰 시장 점유율을 차지하고 있으며, 이는 병원에 기반을 둔 조제에 대한 신뢰와 특수 안과 치료제의 가용성 때문입니다.

북미가 프로스타글란딘 아날로그 시장을 독점하는 것은 고급 건강 관리 인프라와 안과 질환의 높은 유병률 때문입니다. 또한 아시아태평양은 의료투자 증가, 노인 인구 증가, 녹내장과 그 치료법에 대한 의식이 높아지면서 가장 빠르게 성장하는 지역입니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 프로스타글란딘 아날로그 시장 인사이트

  • 스냅샷
  • 프로스타글란딘 아날로그 시장 역학
    • 성장 촉진요인과 기회
      • 안과 질환의 이환율의 상승
      • 약제 처방 및 전달 시스템의 진보
    • 억제요인과 과제
      • 비용과 입수 용이성이 프로스타글란딘 아날로그 시장의 성장을 방해하고 있다
  • PESTEL 분석
  • 프로스타글란딘 아날로그 시장의 투여 경로의 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 프로스타글란딘 아날로그 시장 : 약제 유형별

  • 주요 조사 결과
  • 소개
  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Tafluprost
  • 기타

제6장 세계의 프로스타글란딘 아날로그 시장, 투여 경로별

  • 주요 조사 결과
  • 소개
  • 외용약
  • 경구
  • 주사 가능

제7장 세계의 프로스타글란딘 아날로그 시장 : 용도별

  • 주요 조사 결과
  • 소개
  • 녹내장 치료
  • 분만유도
  • 발기부전
  • 위 보호
  • 기타

제8장 세계의 프로스타글란딘 아날로그 시장 : 유통 채널별

  • 주요 조사 결과
  • 소개
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제9장 세계의 프로스타글란딘 아날로그 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 프로스타글란딘 아날로그 시장 평가:지역, 2019-2032년
  • 북미
    • 북미 : 약제 유형별, 2019-2032년
    • 북미 : 투여 경로별, 2019-2032년
    • 북미 : 용도별, 2019-2032년
    • 북미 : 유통 채널별, 2019-2032년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 약제 유형별, 2019-2032년
    • 유럽: 투여 경로별, 2019-2032년
    • 유럽 : 용도별, 2019-2032년
    • 유럽 : 유통 채널별, 2019-2032년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양: 약제 유형별, 2019-2032년
    • 아시아태평양: 투여 경로별, 2019-2032년
    • 아시아태평양: 용도별, 2019-2032년
    • 아시아태평양: 유통 채널별, 2019-2032년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 약제 유형별, 2019-2032년
    • 중동 및 아프리카: 투여 경로별, 2019-2032년
    • 중동 및 아프리카: 용도별, 2019-2032년
    • 중동 및 아프리카 : 유통 채널별, 2019-2032년
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 약제 유형별, 2019-2032년
    • 라틴아메리카: 투여 경로별, 2019-2032년
    • 라틴아메리카: 용도별, 2019-2032년
    • 라틴아메리카 : 유통 채널별, 2019-2032년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제10장 경쟁 구도

  • 확대 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제11장 기업 프로파일

  • Pfizer Inc.
  • Allergan(an AbbVie company)
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ocular Therapeutix, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV
JHS 24.10.24

The global prostaglandin analogs market size is expected to reach USD 6,566.71 million by 2032, according to a new study by Polaris Market Research. The report "Prostaglandin Analogs Market Size, Share, Trends, Industry Analysis Report: By Route of Administration (Topical, Oral, and Injectable), By Drug Type, By Application, By Distribution Channel, and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The prostaglandin analogs market is a significant segment within the pharmaceutical industry, primarily driven by their role in managing glaucoma. These medications, including Latanoprost, Bimatoprost, and Travoprost, are widely used as the first-line treatment for lowering intraocular pressure (IOP), a critical factor in controlling glaucoma. Their market dominance is attributed to their proven efficacy and favorable safety profile, which have made them the preferred choice for long-term glaucoma management.

Several key factors contribute to the growth of the prostaglandin analogs market. The high prevalence of glaucoma, a leading cause of irreversible blindness, necessitates effective and reliable treatment options. Prostaglandin analogs address this need by significantly reducing IOP and helping prevent vision loss. Additionally, the continuous advancement in drug formulations and delivery systems enhances patient compliance and therapeutic outcomes. Ongoing clinical research into new formulations and combinations further supports market growth by offering improved efficacy and safety profiles.

Overall, the prostaglandin analogs market is driven by the urgent need for effective glaucoma treatments, ongoing innovations, and a growing patient population requiring long-term care.

Prostaglandin Analogs Market Report Highlights:

Latanoprost dominates the prostaglandin analogs market due to its proven efficacy in lowering intraocular pressure in glaucoma patients, making it the most widely prescribed drug within this category.

Topical administration leads the market as it offers targeted treatment with fewer systemic side effects, particularly in the management of ocular conditions such as glaucoma and ocular hypertension.

Glaucoma Treatment is the largest segment, driven by the increasing global prevalence of glaucoma and the effectiveness of prostaglandin analogs in reducing intraocular pressure.

Hospital Pharmacies hold the largest market share, benefiting from the trust in hospital-based dispensing and the availability of specialized ophthalmic treatments.

North America dominates the prostaglandin analogs market, attributed to advanced healthcare infrastructure and a high prevalence of eye disorders. The Asia Pacific is also the fastest-growing region, fueled by increasing healthcare investments, a growing elderly population, and rising awareness about glaucoma and its treatment options.

Polaris Market Research has segmented the prostaglandin analogs market report based on drug type, route of administration, application, distribution channel, and region

Prostaglandin Analogs - Drug Type Outlook (Revenue - USD million, 2019 - 2032)

  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Tafluprost
  • Others

Prostaglandin Analogs - Route of Administration Outlook (Revenue - USD million, 2019 - 2032)

  • Topical
  • Oral
  • Injectable

Prostaglandin Analogs - Application Outlook (Revenue - USD million, 2019 - 2032)

  • Glaucoma Treatment
  • Labor Induction
  • Erectile Dysfunction
  • Gastric Protection
  • Others

Prostaglandin Analogs - Distribution Channel Outlook (Revenue - USD million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Prostaglandin Analogs - Regional Outlook (Revenue - USD million, 2019 - 2032)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prostaglandin Analogs Market Insights

  • 4.1. Prostaglandin Analogs Market -Snapshot
  • 4.2. Prostaglandin Analogs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Ophthalmic Conditions
      • 4.2.1.2. Advancements in Drug Formulations and Delivery Systems
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Cost and Accessibility are hindering the Prostaglandin Analogs market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prostaglandin Analogs Market Route of Administration Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Prostaglandin Analogs Market, by Drug Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
  • 5.3. Latanoprost
    • 5.3.1. Global Prostaglandin Analogs Market, by Latanoprost, by Region, 2019-2032 (USD million)
  • 5.4. Bimatoprost
    • 5.4.1. Global Prostaglandin Analogs Market, by Bimatoprost, by Region, 2019-2032 (USD million)
  • 5.5. Travoprost
    • 5.5.1. Global Prostaglandin Analogs Market, by Travoprost, by Region, 2019-2032 (USD million)
  • 5.6. Tafluprost
    • 5.6.1. Global Prostaglandin Analogs Market, by Tafluprost, by Region, 2019-2032 (USD million)
  • 5.7. Others
    • 5.7.1. Global Prostaglandin Analogs Market, by Others, by Region, 2019-2032 (USD million)

6. Global Prostaglandin Analogs Market, Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
  • 6.3. Topical
    • 6.3.1. Global Prostaglandin Analogs Market, by Topical, by Region, 2019-2032 (USD million)
  • 6.4. Oral
    • 6.4.1. Global Prostaglandin Analogs Market, by Oral, by Region, 2019-2032 (USD million)
  • 6.5. Injectable
    • 6.5.1. Global Prostaglandin Analogs Market, by Injectable, by Region, 2019-2032 (USD million)

7. Global Prostaglandin Analogs Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
  • 7.3. Glaucoma Treatment
    • 7.3.1. Global Prostaglandin Analogs Market, by Glaucoma Treatment, by Region, 2019-2032 (USD million)
  • 7.4. Labor Induction
    • 7.4.1. Global Prostaglandin Analogs Market, by Labor Induction, by Region, 2019-2032 (USD million)
  • 7.5. Erectile Dysfunction
    • 7.5.1. Global Prostaglandin Analogs Market, by Erectile Dysfunction, by Region, 2019-2032 (USD million)
  • 7.6. Gastric Protection
    • 7.6.1. Global Prostaglandin Analogs Market, by Gastric Protection, by Region, 2019-2032 (USD million)
  • 7.7. Others
    • 7.7.1. Global Prostaglandin Analogs Market, by Others, by Region, 2019-2032 (USD million)

8. Global Prostaglandin Analogs Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global Prostaglandin Analogs Market, by Hospital Pharmacies, by Region, 2019-2032 (USD million)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global Prostaglandin Analogs Market, by Retail Pharmacies, by Region, 2019-2032 (USD million)
  • 8.5. Online Pharmacies
    • 8.5.1. Global Prostaglandin Analogs Market, by Online Pharmacies, by Region, 2019-2032 (USD million)

9. Global Prostaglandin Analogs Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Prostaglandin Analogs Market Assessment, By Geography, 2019-2032 (USD million)
  • 9.3. Prostaglandin Analogs Market - North America
    • 9.3.1. North America: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
    • 9.3.2. North America: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
    • 9.3.3. North America: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
    • 9.3.4. North America: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.3.5. Prostaglandin Analogs Market - U.S.
      • 9.3.5.1. U.S.: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.3.5.2. U.S.: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.3.5.3. U.S.: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.3.5.4. U.S.: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.3.6. Prostaglandin Analogs Market - Canada
      • 9.3.6.1. Canada: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.3.6.2. Canada: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.3.6.3. Canada: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.3.6.4. Canada: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
  • 9.4. Prostaglandin Analogs Market - Europe
    • 9.4.1. Europe: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
    • 9.4.2. Europe: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
    • 9.4.3. Europe: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
    • 9.4.4. Europe: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.5. Prostaglandin Analogs Market - UK
      • 9.4.5.1. UK: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.5.2. UK: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.5.3. UK: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.5.4. UK: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.6. Prostaglandin Analogs Market - France
      • 9.4.6.1. France: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.6.2. France: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.6.3. France: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.6.4. France: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.7. Prostaglandin Analogs Market - Germany
      • 9.4.7.1. Germany: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.7.2. Germany: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.7.3. Germany: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.7.4. Germany: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.8. Prostaglandin Analogs Market - Italy
      • 9.4.8.1. Italy: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.8.2. Italy: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.8.3. Italy: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.8.4. Italy: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.9. Prostaglandin Analogs Market - Spain
      • 9.4.9.1. Spain: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.9.2. Spain: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.9.3. Spain: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.9.4. Spain: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.10. Prostaglandin Analogs Market - Netherlands
      • 9.4.10.1. Netherlands: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.10.2. Netherlands: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.10.3. Netherlands: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.10.4. Netherlands: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.11. Prostaglandin Analogs Market - Russia
      • 9.4.11.1. Russia: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.11.2. Russia: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.11.3. Russia: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.11.4. Russia: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.4.12. Prostaglandin Analogs Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.4.12.2. Rest of Europe: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.4.12.3. Rest of Europe: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.4.12.4. Rest of Europe: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
  • 9.5. Prostaglandin Analogs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
    • 9.5.2. Asia Pacific: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
    • 9.5.3. Asia Pacific: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
    • 9.5.4. Asia Pacific: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.5. Prostaglandin Analogs Market - China
      • 9.5.5.1. China: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.5.2. China: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.5.3. China: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.5.4. China: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.6. Prostaglandin Analogs Market - India
      • 9.5.6.1. India: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.6.2. India: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.6.3. India: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.6.4. India: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.7. Prostaglandin Analogs Market - Malaysia
      • 9.5.7.1. Malaysia: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.7.2. Malaysia: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.7.3. Malaysia: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.7.4. Malaysia: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.8. Prostaglandin Analogs Market - Japan
      • 9.5.8.1. Japan: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.8.2. Japan: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.8.3. Japan: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.8.4. Japan: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.9. Prostaglandin Analogs Market - Indonesia
      • 9.5.9.1. Indonesia: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.9.2. Indonesia: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.9.3. Indonesia: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.9.4. Indonesia: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.10. Prostaglandin Analogs Market - South Korea
      • 9.5.10.1. South Korea: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.10.2. South Korea: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.10.3. South Korea: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.10.4. South Korea: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.11. Prostaglandin Analogs Market - Australia
      • 9.5.11.1. Australia: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.11.2. Australia: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.11.3. Australia: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.11.4. Australia: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.5.12. Prostaglandin Analogs Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.5.12.2. Rest of Asia Pacific: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.5.12.3. Rest of Asia Pacific: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.5.12.4. Rest of Asia Pacific: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
  • 9.6. Prostaglandin Analogs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
    • 9.6.2. Middle East & Africa: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
    • 9.6.3. Middle East & Africa: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
    • 9.6.4. Middle East & Africa: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.6.5. Prostaglandin Analogs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.6.5.2. Saudi Arabia: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.6.5.3. Saudi Arabia: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.6.5.4. Saudi Arabia: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.6.6. Prostaglandin Analogs Market - UAE
      • 9.6.6.1. UAE: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.6.6.2. UAE: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.6.6.3. UAE: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.6.6.4. UAE: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.6.7. Prostaglandin Analogs Market - Israel
      • 9.6.7.1. Israel: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.6.7.2. Israel: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.6.7.3. Israel: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.6.7.4. Israel: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.6.8. Prostaglandin Analogs Market - South Africa
      • 9.6.8.1. South Africa: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.6.8.2. South Africa: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.6.8.3. South Africa: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.6.8.4. South Africa: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.6.9. Prostaglandin Analogs Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.6.9.2. Rest of Middle East & Africa: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.6.9.3. Rest of Middle East & Africa: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.6.9.4. Rest of Middle East & Africa: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
  • 9.7. Prostaglandin Analogs Market - Latin America
    • 9.7.1. Latin America: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
    • 9.7.2. Latin America: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
    • 9.7.3. Latin America: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
    • 9.7.4. Latin America: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.7.5. Prostaglandin Analogs Market - Mexico
      • 9.7.5.1. Mexico: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.7.5.2. Mexico: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.7.5.3. Mexico: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.7.5.4. Mexico: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.7.6. Prostaglandin Analogs Market - Brazil
      • 9.7.6.1. Brazil: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.7.6.2. Brazil: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.7.6.3. Brazil: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.7.6.4. Brazil: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.7.7. Prostaglandin Analogs Market - Argentina
      • 9.7.7.1. Argentina: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.7.7.2. Argentina: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.7.7.3. Argentina: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.7.7.4. Argentina: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)
    • 9.7.8. Prostaglandin Analogs Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Prostaglandin Analogs Market, by Drug Type, 2019-2032 (USD million)
      • 9.7.8.2. Rest of Latin America: Prostaglandin Analogs Market, by Route of Administration, 2019-2032 (USD million)
      • 9.7.8.3. Rest of Latin America: Prostaglandin Analogs Market, by Application, 2019-2032 (USD million)
      • 9.7.8.4. Rest of Latin America: Prostaglandin Analogs Market, by Distribution Channel, 2019-2032 (USD million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Pfizer Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Per Distribution Channel
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Allergan (an AbbVie company)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Per Distribution Channel
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Novartis AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Per Distribution Channel
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bayer AG
    • 11.4.1. Company Overview
    • 11.4.2. Financial Per Distribution Channel
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. GlaxoSmithKline plc
    • 11.5.1. Company Overview
    • 11.5.2. Financial Per Distribution Channel
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Merck & Co., Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Per Distribution Channel
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Santen Pharmaceutical Co., Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Per Distribution Channel
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Ocular Therapeutix, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Per Distribution Channel
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Aerie Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Per Distribution Channel
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Sun Pharmaceutical Industries Ltd.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Per Distribution Channel
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Lupin Pharmaceuticals, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Per Distribution Channel
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Per Distribution Channel
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Hikma Pharmaceuticals PLC
    • 11.13.1. Company Overview
    • 11.13.2. Financial Per Distribution Channel
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Mylan N.V.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Per Distribution Channel
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제